Guselkumab: A Breakthrough In Treating Moderate To Severe Psoriasis

Psoriasis is a chronic, inflammatory skin disorder that affects millions of people around the world. For years, medical professionals have been searching for effective treatment and now there may be one on the horizon. Guselkumab is a new monoclonal antibody therapy that is showing promising results in treating moderate to severe psoriasis. In this blog post, you’ll learn more about this breakthrough and how it could revolutionize the way we treat Psoriasis. We will also discuss the potential side effects, cost, and availability of Guselkumab.

What is guselkumab?

Guselkumab (trade name Tremfya) is a human monoclonal antibody that binds to interleukin-23 (IL-23) and inhibits its function. IL-23 is a cytokine that plays a key role in the pathogenesis of psoriasis. Guselkumab was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Guselkumab is administered as an intravenous infusion or subcutaneous injection. The recommended dose is 100 mg every 4 weeks for 3 doses, then every 8 weeks thereafter. Guselkumab can be used with or without concurrent topical corticosteroids or calcipotriene. The most common adverse reactions (>= 1%) observed in clinical trials were injection site reactions, upper respiratory tract infections, headaches, and diarrhea. Guselkumab has been associated with rare but serious adverse events such as tuberculosis and hypersensitivity reactions.

How does guselkumab work?

Guselkumab works by targeting the protein interleukin-23 (IL-23). IL-23 is a cytokine, which is a type of protein that plays a role in inflammatory and immune responses. Cytokines are involved in a wide range of biological processes, including cell growth, differentiation, and Apremilast (Otezla) migration. They also play an important role in the body's response to infection and injury. Guselkumab works by binding to IL-23 and preventing it from attaching to its receptor on the surface of cells. This helps to reduce inflammation and the overproduction of skin cells that characterizes psoriasis.

What are the benefits of guselkumab?

Guselkumab is a breakthrough monoclonal antibody that targets interleukin-23 (IL-23), a cytokine involved in the pathogenesis of psoriasis. Guselkumab has shown efficacy in clinical trials in reducing the signs and symptoms of moderate to severe plaque psoriasis. The benefits of guselkumab include: Reduction in the severity of psoriasis symptoms, Improvement in quality of life, Reduced itching and burning sensations, Reduced skin redness and inflammation. Guselkumab is well tolerated with a favorable safety profile. The most common adverse reactions are upper respiratory tract infections, headaches, and diarrhea. 

What are the side effects of guselkumab? 

Guselkumab is a monoclonal antibody that works by targeting and inhibiting interleukin-23 (IL-23), a protein that plays a key role in the development of moderate to severe psoriasis. Common side effects of guselkumab include upper respiratory tract infections, headaches, and dizziness. Less common side effects include gastrointestinal problems such as nausea, vomiting, and diarrhea. In rare cases, more serious side effects such as hypersensitivity reactions and Serious Infections may occur.

Who should not take guselkumab?

Guselkumab is not right for everyone. The people who should not take guselkumab: are allergic to guselkumab or any of its ingredients, have a history of tuberculosis (TB) or have been in close contact with someone with TB, have any other medical conditions, are pregnant or plan to become pregnant. It is not known if guselkumab will harm unborn baby, are breastfeeding or plan to breastfeed. It is not known if guselkumab passes into your breast milk. 

Conclusion

Guselkumab has proven to be a breakthrough in treating moderate to severe psoriasis. It is an effective and safe treatment, resulting in rapid clearance of lesions with a sustained response over long-term follow-up. This provides medical professionals the confidence that this monoclonal antibody can provide much-needed relief for their patients who suffer from this chronic condition. With its demonstrated efficacy, safety profile, and convenient dosing regimen, guselkumab should be considered as an option when prescribing treatment for moderate-to-severe plaque psoriasis.